The announcement of a drug shortage by the FDA directly impacts Novo Nordisk (NVO) as the manufacturer of Wegovy. This situation could lead to short-term negative sentiment among investors, concerned about the potential impact on sales and revenue. However, the exact duration of the shortage and its full impact on the company's financials are still uncertain, which is reflected in the confidence score.